Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS1 | P23219 | 2/20 | 0.41 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.41 |
| ▸ | GSK3B | P49841 | 8/20 | 0.41 |
| ▸ | ATM | Q13315 | 1/20 | 0.41 |
| ▸ | PTPN1 | P18031 | 4/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | GNG2 | P59768 | 1/20 | 0.39 |
| ▸ | GNB1 | P62873 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | CTNNB1 | P35222 | 1/20 | 0.38 |
| ▸ | WNT3A | P56704 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | PKM | P14618 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15188490 | 0.85 | PTPN1 (0.41) | PTGS1PTGS2GSK3BATMPTPN1 | |
| SCHEMBL15188495 | 0.81 | KDM4E (0.49) | PTGS1PTGS2MEN1KMT2A | |
| SCHEMBL15188478 | 0.80 | ALDH1A1 (0.54) | GSK3BATMPTPN1HPGDCTNNB1 | |
| SCHEMBL15188473 | 0.80 | ALDH1A1 (0.50) | GSK3BATMPTPN1HPGDCTNNB1 | |
| SCHEMBL15176562 | 0.80 | MEN1 (0.40) | PTGS1PTGS2ATMCYP2C9MEN1 | |
| SCHEMBL15188511 | 0.79 | GSK3B (0.38) | PTGS1PTGS2GSK3BHPGDCYP2C9 | |
| SCHEMBL881345 | 0.79 | KDM4E (0.50) | GSK3BATMHPGDCTNNB1WNT3A | |
| SCHEMBL15188476 | 0.78 | PTPN1 (0.49) | GSK3BPTPN1 | |
| SCHEMBL12467535 | 0.72 | ATM (0.43) | ATMPTPN1HPGDCTNNB1WNT3A | |
| SCHEMBL12467520 | 0.72 | ATM (0.43) | ATMPTPN1HPGDCTNNB1WNT3A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9073943-B2 | Antiviral compounds with a dibenzooxaheterocycle moiety | LUPIN LIMITED (IN) | 2015-07-07 | — | — | US | disclosed |
| US-9073943-B2 | Antiviral compounds with a dibenzooxaheterocycle moiety | LUPIN LIMITED (IN) | 2015-07-07 | — | — | US | disclosed |
| US-9073943-B2 | Antiviral compounds with a dibenzooxaheterocycle moiety | LUPIN LIMITED (IN) | 2015-07-07 | — | — | US | disclosed |
| US-20150010505-A1 | Antiviral Compounds with a Dibenzooxaheterocycle Moiety | LUPIN LIMITED (IN) | 2015-01-08 | — | — | US | disclosed |
| US-20150010505-A1 | Antiviral Compounds with a Dibenzooxaheterocycle Moiety | LUPIN LIMITED (IN) | 2015-01-08 | — | — | US | disclosed |
| US-20150010505-A1 | Antiviral Compounds with a Dibenzooxaheterocycle Moiety | LUPIN LIMITED (IN) | 2015-01-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150010505-A1 | Antiviral Compounds with a Dibenzooxaheterocycle Moiety | DDX6, HAVCR2, DHX36 | PTGS1 2489/4885PTGS2 2785/4885GSK3B 3530/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.